Update on the Vamorolone Program

We will provide an update on the scientific rationale for use of vamorolone, and share some results from our open-label Long Term Extension study. The very important pivotal clinical trial is now seeking participants; we will review information about this trial. ReveraGen was recently awarded a grant to study family and physician preferences regarding the return of individual and aggregate clinical trial data to participant families. Finally, we will discuss ReveraGen’s unique funding model.